デュークラバシチニブ

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H372：長期にわたる、または反復暴露により臓器の障 害

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P314：気分が悪い時は、医師の診断/手当てを受けること。

  P501：内容物/容器を．．．に廃棄すること。

デュークラバシチニブ 化学特性,用途語,生産方法

• 効能

  抗炎症薬, チロシンキナーゼ2阻害薬

• 説明

  Deucravacitinib (trade name Sotykto) is a first-in-class tyrosine kinase 2 (TYK2) inhibitor recently approved for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin disease characterized by the formation of red patches and scaling on the skin. Discovered by Bristol Myers Squibb (BMS), deuterated colestitinib, also known as BMS-986165, is the first JAK inhibitor containing deuterium and the first approved selective TYK2 inhibitor, showing more than 50,000-fold selectivity over JAK1, JAK2 and JAK3.

• 一般的な説明

  Deucravacitinib, a highly selective allosteric TYK2 inhibitor, received its first approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy protein and lipid kinases and pseudokinases with the exception of BMPR2 (IC50 = 193 nM) and JAK1 JH2 pseudokinase domain (IC50 = 1 nM). Despite its potent affinity for JAK1 JH2, deucravacitinib elicited low functional activity in a JAK1/JAK3-dependent IL-2 stimulated cellular assay. BMS-986202 displays >10,000-fold selectivity for TYK2 JH2 over a diverse panel of 273 kinases and pseudokinases that include JAK family members. Like deucravacitinib, its high binding affinity to JAK1 JH2 (IC50 = 7.8 nM) did not translate to functional activity in the cellular assay.

デュークラバシチニブ 上流と下流の製品情報

デュークラバシチニブ 生産企業

Global(254)Suppliers

デュークラバシチニブ スペクトルデータ(¹HNMR)

1609392-27-9, デュークラバシチニブ キーワード